Industry News

Biotechnology Industry News

With a few chemical tweaks and…

April 16th, 2026|FierceBiotech|

With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics.

China’s biotech rise has been a…

April 16th, 2026|FierceBiotech|

China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring. 

After its bet on a rare eye…

April 16th, 2026|FierceBiotech|

After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning the asset to sender as MeiraGTx buys back back full rights to botaretigene sparoparvovec

Aligos Therapeutics has secured a…

April 16th, 2026|FierceBiotech|

Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) treatment.

A slow start to 2026 has put…

April 16th, 2026|FierceBiotech|

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.

The Spanish government has…

April 15th, 2026|FierceBiotech|

The Spanish government has announced a goal to raise a $200 million venture capital fund to launch the Spain-Boston biotechnology initiative to expand international collaboration.

Terremoto Biosciences has spelt…

April 15th, 2026|FierceBiotech|

Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to continue its efforts to broaden the covalent drug alphabet.

The FDA’s newly launched…

April 14th, 2026|FierceBiotech|

The FDA’s newly launched plausible mechanism framework may have been forged in the image of individualized therapies, but its principles are not confined to the bespoke, Teresa Buracchio, M.D., head of the FDA’s Office of

After initiating a wind-down more…

April 14th, 2026|FierceBiotech|

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.

Takeda has pulled back from a…

April 14th, 2026|FierceBiotech|

Takeda has pulled back from a research collaboration with a fellow Japanese life sciences company, ending work to discover new small molecules that target mRNA.

Eli Lilly has turned its attention…

April 13th, 2026|FierceBiotech|

Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (ADCs) pipeline.

An FDA review of records found…

April 13th, 2026|FierceBiotech|

An FDA review of records found that results have not been reported for 30% of registered clinical studies. To remedy this shortfall, the U.S. regulator has sent reminders to 2,200 drug companies, medical device manufacturers